PF-06671008 Dose Escalation Study in Advanced Solid Tumors

Status:	Active, not recruiting
Conditions:	Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	4/5/2019
Start Date:	April 28, 2016
End Date:	April 4, 2019

A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS

The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses
of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin
expression. The study will then expand to look at the selected dose in patients with
P-cadherin expressing TNBC, CRC or NSCLC.

Key Inclusion Criteria

- Diagnosis of tumor type with the potential to have P-cadherin expression that is
resistant to standard therapy or for which no standard therapy is available

- Performance status of 0 or 1

- Adequate bone marrow, kidney and liver function

Key Exclusion Criteria

- Known CNS disease including, but not limited to, metastases

- Current or history of seizure disorder

- History of or active autoimmune disorders

- Active bacterial, fungal or viral infection

- Major surgery, anti-cancer therapy, or radiation therapy within 4 weeks of study
treatment

- Requirement for systemic immune suppressive medication

- Grade 2 or greater peripheral neuropathy

We found this trial at

sites

Memorial Sloan Kettering Cancer Center

1275 York Ave
New York, New York 10021

(212) 639-2000